| Titre : | Access to cannabidiol without a prescription: A cross-country comparison and analysis (2020) |
| Auteurs : | I. S. MCGREGOR ; E. A. CAIRNS ; S. ABELEV ; R. COHEN ; M. HENDERSON ; D. COUCH ; J. C. ARNOLD ; N. GAULD |
| Type de document : | Article : Périodique |
| Dans : | International Journal of Drug Policy (Vol.85, November 2020) |
| Article en page(s) : | art. 102935 |
| Langues: | Anglais |
| Discipline : | LOI (Loi et son application / Law enforcement) |
| Mots-clés : |
Thésaurus TOXIBASE COMPARAISON ; CANNABINOIDES ; LEGISLATION ; USAGE THERAPEUTIQUE ; DIFFUSION DES PRODUITS ; CANNABISThésaurus Géographique ETATS-UNIS ; CANADA ; ALLEMAGNE ; IRLANDE ; ROYAUME-UNI ; SUISSE ; JAPON ; AUSTRALIE ; NOUVELLE ZELANDE |
| Mots-clés: | cannabidiol |
| Résumé : |
Background: Recent legislative change has allowed increased access to cannabis products in many jurisdictions. In some locations, this includes over-the-counter (OTC) and/or online access to products containing cannabidiol (CBD), a non-intoxicating cannabinoid with therapeutic properties. Here we compared the availability of CBD products and the associated legislative and regulatory background in nine selected countries.
Methods: Accessibility of CBD products was examined in the USA, Canada, Germany, Ireland, United Kingdom, Switzerland, Japan, Australia, and New Zealand as of May 2020. Regulatory and other relevant documents were obtained from government agency websites and related sources. Relevant commercial websites and some physical retailers were visited to verify access to CBD-containing products and the nature of the products available. Results: A range of CBD products appeared to be accessible without prescription in seven out of nine countries reviewed. Australia and New Zealand were the exceptions where clinician prescription was required to access any CBD-containing product. CBD products commonly available without prescription included oils, gel capsules, purified crystal and topical products. The daily recommended doses with orally administered non-prescription products were typically well below 150 mg and substantially lower than the doses reported to have therapeutic effects in published clinical trials (e.g., 300-1500 mg). The legal foundations enabling access in several countries were often unclear, with marketed products sometimes failing to meet legal requirements for sale. There was an obvious disparity between federal directives and available products in both the USA and European countries examined. Conclusions: There are a variety of approaches in how countries manage access to CBD products. Many countries appear to permit OTC and online availability of CBD products but often without legislative clarity. As consumer demand for CBD escalates, improved legislation, guidelines and quality control of CBD products would seem prudent together with clinical trials exploring the therapeutic benefits of lower-dose CBD formulations. |
| Domaine : | Autres substances / Other substances ; Drogues illicites / Illicit drugs |
| Affiliation : | The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia |
| Cote : | Abonnement |
Accueil
